匹伐他汀与阿托伐他汀对冠状动脉旁路移植术后早期患者调节血脂的对比研究

Comparative study between pitavastatin and atorvastatin in lowering blood lipid in patients early after coronary artery bypass graft

目的对比匹伐他汀(2 mg)和阿托伐他汀(20 mg)对冠状动脉旁路移植术(CABG)后早期血脂控制的效果及安全性。方法以单中心非盲随机对照的方式对196位受试者开展为期12周的临床研究。结果术后12周匹伐他汀组和阿托伐他汀组的总胆固醇(TC),低密度脂蛋白胆固醇(LDL-C)和三酰甘油(TG)较基线水平均显著降低(均P<0.05),但组间无显著差异;两组患者的高密度脂蛋白胆固醇(HDL-C)较基线水平有所升高(P<0.05),但组间无显著差异;术后1周时,两组的丙氨酸氨基转氨酶(ALT),门冬氨酸氨基转氨酶(AST)及肌酸激酶(CK)较基线水平均有所升高,但阿托伐他汀组的ALT及CK较匹伐他汀组更高;术后12周匹伐他汀组的ALT,AST及CK较基线水平无显著变化,阿托伐他汀的ALT及CK较基线水平增高,但两组间无显著差异。结论 2 mg匹伐他汀与20 mg阿托伐他汀有相似的降低TC,LDL-C,TG及升高HDL-C的作用。

AIM To evaluate the efficacy and safety of pitavastatin （2 mg） and atorvastatin （20mg） in lowering blood lipids in coronary artery bypass graft （CABG） patients. METHODS An open-blind randomized control trial was conducted in single cardiac center with 196 CABG patients for 12 weeks. RESULTS TC, LDL-C and TG levels at the 12th week after CABG decreased significantly compared with baseline （P〈0.05）. There were no differences between the two groups. HDL-C levels increased at the 12th week when compared with baseline （P〈0.05）. There were no differences between the two groups. ALT, AST and CK levels increased at the 1st week when compared with baseline and the ALT and CK levels were higher in the atorvastatin group. ALT, AST and CK levels were no different to baseline levels at the 12th week after CABG in the pitavastatin group, but ALT and CK levels in the atorvastatin group were higher when compared with baseline. CONCLUSION Pitavastatin is a safe and effective medication for lowering blood lipid in patients after CABG. Pitavastatin （2 mg） and atorvastatin （20 mg） can achieve similar effects in decreasing TC, LDL-C and TG levels and increasing HDL-C levels.